Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Ensartinib |
Trade Name | Ensacove |
Synonyms | X-396 |
Drug Descriptions |
Ensacove (ensartinib) is a small molecule inhibitor of ALK, which inhibits downstream signaling and potentially leads to decreased growth of ALK-expressing tumors (PMID: 21613408, PMID: 31628085). Ensacove (ensartinib) is FDA-approved for use in adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK-inhibitor (FDA.gov). |
DrugClasses | ALK Inhibitor 33 |
CAS Registry Number | 1370651-20-9 |
NCIT ID | C102754 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Carboplatin + Ensartinib + Pemetrexed Disodium | Bevacizumab Carboplatin Ensartinib Pemetrexed Disodium | 0 | 1 |
Carboplatin + Ensartinib | Carboplatin Ensartinib | 0 | 1 |
Cisplatin + Ensartinib | Cisplatin Ensartinib | 0 | 1 |
Denosumab + Ensartinib | Denosumab Ensartinib | 0 | 0 |
Durvalumab + Ensartinib | Durvalumab Ensartinib | 0 | 1 |
Ensartinib | Ensartinib | 45 | 8 |
Ensartinib + Fruquintinib | Ensartinib Fruquintinib | 0 | 0 |
Ensartinib + Pralsetinib | Ensartinib Pralsetinib | 0 | 0 |
Ensartinib + Sirolimus | Ensartinib Sirolimus | 1 | 0 |